BREXPIPRAZOLE
Total Payments
$3.4M
Transactions
397
Doctors
66
Companies
2
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2018 | $59,088 | 55 | 19 |
| 2017 | $3.3M | 342 | 52 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $3.3M | 320 | 98.0% |
| Consulting Fee | $46,033 | 27 | 1.4% |
| Travel and Lodging | $21,135 | 31 | 0.6% |
| Food and Beverage | $894.23 | 15 | 0.0% |
| Education | $711.92 | 2 | 0.0% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $118.98 | 2 | 0.0% |
Payments by Type
Research
$3.3M
320 transactions
General
$68,894
77 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A STUDY OF THREE FIXED-DOSES OF BREXPIPRAZOLE IN THE TREATMENT OF SUBJECTS WITH AGITATION ASSOCIATED WITH DEMENTIA OF THE ALZHEIMER'S TYPE | Otsuka Pharmaceutical Development & Commercialization, Inc. | $965,567 | 8 |
| SAFETY AND TOLERABILITY STUDY OF FLEXIBLE DOSING OF BREXPIPRAZOLE IN THE TREATMENT OF SUBJECTS WITH AGITATION ASSOCIATED WITH DEMENTIA OF THE ALZHEIMER'S TYPE | Otsuka Pharmaceutical Development & Commercialization, Inc. | $917,347 | 2 |
| A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF BREXPIPRAZOLE PLUS KETAMINE IN TREATMENT-RESISTANT DEPRESSION TRD | Otsuka Pharmaceutical Development & Commercialization, Inc. | $874,859 | 0 |
| A STUDY OF FLEXIBLE-DOSE BREXPIPRAZOLE AS ADJUNCTIVE THERAPY IN THE TREATMENT OF ADULTS WITH MAJOR DEPRESSIVE DISORDER | Otsuka Pharmaceutical Development & Commercialization, Inc. | $312,494 | 1 |
| SAFETY FOLLOW-UP STUDY FOR SUBJECTS WITH AGITATION ASSOCIATED WITH DEMENTIA OF THE ALZHEIMER'S TYPE WHO PREVIOUSLY PARTICIPATED IN A DOUBLE-BLIND TRIAL OF BREXPIPRAZOLE OR PLACEBO | Otsuka Pharmaceutical Development & Commercialization, Inc. | $105,803 | 3 |
| BREXPIPRAZOLE FOR BIPOLAR DEPRESSION | Otsuka Pharmaceutical Development & Commercialization, Inc. | $83,301 | 0 |
| A Phase 2, Multicenter, Randomized, Double-blind, Placebo- and Active-controlled Trial | Otsuka Pharmaceutical Development & Commercialization, Inc. | $37,466 | 32 |
| A 2-MONTH, OBSERVATIONAL, ROLLOVER TRIAL TO EVALUATE THE SAFETY OF SUBJECTS WITH AGITATION ASSOCIATED WITH DEMENTIA OF THE ALZHEIMERS TYPE WHO WERE PREVIOUSLY TREATED WITH BREXPIPRAZOLE OPC-34712 OR PLACEBO IN A PHASE 3, DOUBLE-BLIND TRIAL | Otsuka Pharmaceutical Development & Commercialization, Inc. | $975.76 | 0 |
Top Doctors Receiving Payments for BREXPIPRAZOLE — Page 2
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| , MD | Psychiatry | Atlanta, GA | $1,353 | 6 |
| , M.D | Psychiatry | Garden City, NY | $1,318 | 7 |
| , MD | Neurology | Quincy, MA | $1,312 | 1 |
| , MD | Psychiatry | Salem, OR | $1,298 | 7 |
| , MD | Psychiatry | Olive Branch, MS | $1,285 | 7 |
| , M.D | Psychiatry | Phoenix, AZ | $1,253 | 6 |
| , MD | Internal Medicine | Salem, OR | $1,252 | 7 |
| , M.D | Psychiatry | Oceanside, CA | $1,247 | 7 |
| , M.D | Psychiatry | Baltimore, MD | $1,246 | 5 |
| , M.D | Psychiatry | Tamarac, FL | $1,244 | 7 |
| , M.D | Psychiatry | Banning, CA | $1,228 | 6 |
| , MD | Psychiatry | Houston, TX | $1,193 | 7 |
| , MD | Psychiatry | Longwood, FL | $1,180 | 6 |
| , MD | Psychiatry | Marietta, GA | $1,149 | 7 |
| , M.D | Psychiatry | Northbrook, IL | $1,146 | 7 |
| , MD | Child & Adolescent Psychiatry | Cleveland, OH | $1,113 | 1 |
| , MD | Geriatric Psychiatry | St Augustine, FL | $1,106 | 4 |
| , MD | Psychiatry | Atlanta, GA | $1,105 | 6 |
| , M.D | Specialist | New York, NY | $1,098 | 5 |
| , M.D | Psychiatry | Saint Charles, MO | $1,095 | 3 |
| , MD | Psychiatry | University Park, FL | $1,075 | 6 |
| , M.D | Psychiatry | Lauderhill, FL | $1,065 | 6 |
| , D.O | Psychiatry | Tulsa, OK | $1,063 | 6 |
| , M.D | Psychiatry | Baltimore, MD | $1,029 | 6 |
| , M.D | Psychiatry | Norristown, PA | $1,023 | 2 |
Ad
Manufacturing Companies
Product Information
- Type Drug
- Total Payments $3.4M
- Total Doctors 66
- Transactions 397
About BREXPIPRAZOLE
BREXPIPRAZOLE is a drug associated with $3.4M in payments to 66 healthcare providers, recorded across 397 transactions in the CMS Open Payments database. The primary manufacturer is Otsuka Pharmaceutical Development & Commercialization, Inc..
Payment data is available from 2017 to 2018. In 2018, $59,088 was paid across 55 transactions to 19 doctors.
The most common payment nature for BREXPIPRAZOLE is "Unspecified" ($3.3M, 98.0% of total).
BREXPIPRAZOLE is associated with 8 research studies, including "A STUDY OF THREE FIXED-DOSES OF BREXPIPRAZOLE IN THE TREATMENT OF SUBJECTS WITH AGITATION ASSOCIATED WITH DEMENTIA OF THE ALZHEIMER'S TYPE" ($965,567).